[Current progress in antifungal therapy: the value of fluconazole].
Invasive fungal infections are major problems in immunocompromised patients and optimal therapeutical modalities are still far from optimal. Recently, progresses of antifungal therapy have been achieved with the development of new antifungal agents. In particular, fluconazole seems very promising due to the availability of oral and intravenous formulations. Tolerance and compliance of patients are excellent and side effects as well as interaction with other drugs are less commonly observed than with other antifungal agents available so far. The major indications of fluconazole are candidiasis and cryptococcosis.
Meunier
F
F
Service de Médecine Interne, Institut Jules Bordet, Université Libre de Bruxelles, Belgique.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D002180:Candidiasis, Oral / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D015725:Fluconazole / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*
D015725:Fluconazole
Progrès récents de la thérapeutique antifongique: intérêt du fluconazole.